A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)
| Title | A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) |
|---|---|
| Description | A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) study will assess the efficacy and safety of durvalumab and olaparib when added to standard of care (SoC) in patients with newly diagnosed advanced ovarian cancer. The study consists of 2 independent cohorts which are defined by the breast cancer sensitivity gene (BRCA) mutated (BRCAm) status, based on testing of tumour tissue (ie, tBRCAm status) of the patients. |
| Organism | Homo sapiens |
| Data Type | Other Type of Genomic Data |
| Data Accessibility | Open-access |
| BioProject | PRJCA015596 |
| Release Date | 2023-03-22 |
| Submitter | Rutie Yin (yrtt2013@163.com) |
| Organization | West China The Second Hospital |
| Submission Date | 2023-03-21 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX003417-01 | DUO-O patient BRCA/HRD tests | 2 | Other Type of Genomic Data | 15.2 KB | xlsx | 0 | Unavailable |